Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US.

ABSTRACT:

Importance

While immunotherapy is being used in an expanding range of clinical scenarios, the incidence of immunotherapy initiation at the end of life (EOL) is unknown.

Objective

To describe patient characteristics, practice patterns, and risk factors concerning EOL-initiated (EOL-I) immunotherapy over time.

Design, setting, and participants

Retrospective cohort study using a US national clinical database of patients with metastatic melanoma, non-small cell lung cancer (NSCLC), or kidney cell carcinoma (KCC) diagnosed after US Food and Drug Administration approval of immune checkpoint inhibitors for the treatment of each disease through December 2019. Mean follow-up was 13.7 months. Data analysis was performed from December 2022 to May 2023.

Exposures

Age, sex,

SUBMITTER: Kerekes DM 

PROVIDER: S-EPMC10767643 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature